drugset / Trial / NCT06612151
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
Timeline
- Start
- 2024-12-17
- Primary completion
- 2027-12-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Topotecan | Small molecule | — | Intravenous |
| Subject | YL201 | Other / unclassified | — | Intravenous |